Oxyntomodulin: Actions and role in diabetes.

Jens J Holst, Nicolai J Wewer Albrechtsen, Maria Buur Nordskov Gabe, Mette Marie Rosenkilde

Journal: Peptides 2018;100():48-53

PMID: 29412831

Full Text on Elsevier Science View on PubMed

Abstract

Oxyntomodulin is a product of the glucagon precursor, proglucagon, produced and released from the endocrine L-cells of the gut after enzymatic processing by the precursor prohormone convertase 1/3. It corresponds to the proglucagon sequence 33-69 and thus contains the entire glucagon sequence plus a C-terminal octapeptide, comprising in total 37 amino acids. As might have been expected, it has glucagon-like bioactivity, but also and more surprisingly also activates the receptor for GLP-1. This has given the molecule an interesting status as a glucagon-GLP-1 co-agonist, which is currently attracting considerable interest for its potential in the treatment of diabetes and obesity. Here, we provide an update on oxyntomodulin with a focus on its potential role in metabolic diseases.

Address: Department of Biomedical Sciences & Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. Electronic address: [email protected].; Department of Biomedical Sciences & Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

DOI: 10.1016/j.peptides.2017.09.018

Link outs

Free resources

Medical:

https://medlineplus.gov/obesity.html

Other Literature Sources:

Research Materials:

https://antibodies.cancer.gov/detail/CPTC-HLA-B-1

Subscription / membership required

Full Text Sources:

MeSH Terms: Amino Acids, Diabetes Mellitus, Glucagon, Humans, Obesity, Oxyntomodulin, Proglucagon, Proprotein Convertases